The agency removed some onerous requirements for the complex cancer drugs and reduced restrictions on patients’ ...

Biocryst is offloading part of its business for $250 million. Meanwhile, the former FDA leader took issue with a new policy ...

Thimerosal, targeted by activists who claim it’s linked to autism, shouldn't be used in vaccines given in the U.S. this ...

The biotech, which earlier this year laid off nearly all of its staff, also announced a PIPE that will hand it $175 million ...

The brain drug developer is now saying that its two marketed products could ultimately bring in $2 billion annually, and its ...

Bill Meury, who shepherded Karuna and Anthos to multibillion-dollar buyouts, will take over Incyte, a successful drug ...

New members of the ACIP panel raised questions about the evidence supporting COVID vaccines, and signaled plans to look at ...

The biotech will work on molecular glue degraders with Gilead in a new deal. Existing partner Sanofi changed its focus to a ...

The agency said it will evaluate whether regulatory action is needed after investigating the deaths of two patients treated with Sarepta's therapy.

Backed by Perceptive Xontogeny Venture Funds and venBio Partners, the new biotech will make genetic medicines that don’t rely ...

The GOP senator objected to Secretary Kennedy's recasting of the influential advisory panel, which has sparked criticism from ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...